Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study

Treatment sequence of cetuximab and immune checkpoint inhibitor in head and neck squamous cell carcinoma differentially affects outcomes

(2020) Jong Chul Park et al.   ORAL ONCOLOGY

Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use

(2019) Robert L. Ferris et al.   CLINICAL CANCER RESEARCH

Nivolumab versus investigator’s choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age

(2019) Nabil F. Saba et al.   ORAL ONCOLOGY

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

(2019) Barbara Burtness et al.   LANCET

Targeting the EGFR and Immune Pathways in Squamous Cell Carcinoma of the Head and Neck (SCCHN): Forging a New Alliance

(2019) Nabil F. Saba et al.   MOLECULAR CANCER THERAPEUTICS

Human Papillomavirus Testing in Head and Neck Carcinomas: Guideline From the College of American Pathologists

(2018) James S. Lewis et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression

(2018) Robert L. Ferris et al.   ORAL ONCOLOGY

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

(2018) Ezra E W Cohen et al.   LANCET

Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial

(2018) Maura L Gillison et al.   LANCET

Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial

(2017) Kevin J Harrington et al.   LANCET ONCOLOGY

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

(2016) Robert L. Ferris et al.   NEW ENGLAND JOURNAL OF MEDICINE

CTLA-4+Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis

(2015) Hyun-Bae Jie et al.   CANCER RESEARCH

The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies

(2015) Leisha A. Emens et al.   Cancer Immunology Research

p16 Protein Expression and Human Papillomavirus Status As Prognostic Biomarkers of Nonoropharyngeal Head and Neck Squamous Cell Carcinoma

(2014) Christine H. Chung et al.   JOURNAL OF CLINICAL ONCOLOGY

Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen-Specific T-cell Immunity in Head and Neck Cancer Patients

(2013) R. M. Srivastava et al.   CLINICAL CANCER RESEARCH

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer

(2010) K. Kian Ang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Distinct Risk Factor Profiles for Human Papillomavirus Type 16–Positive and Human Papillomavirus Type 16–Negative Head and Neck Cancers

(2008) Maura L. Gillison et al.   JNCI-Journal of the National Cancer Institute

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

(2008) Jan B. Vermorken et al.   NEW ENGLAND JOURNAL OF MEDICINE